


下載本文檔
版權說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權,請進行舉報或認領
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEScopolamine hydrobromideCat. No.: HY-N0296ACAS No.: 114-49-8Synonyms: (-)-Scopolamine hydrobromide; Hyoscine hydrobromide;Scopine hydrobromide分式: CHBrNO分量: 384.26作靶點: mAChR; 5-HT Receptor作通路: GPCR/G Protein; Neuronal Signaling儲存
2、式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 H2O : 100 mg/mL (260.24 mM)DMSO : 32 mg/mL (83.28 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.6024 mL 13.0120 mL 26.0240 mL5 mM 0.5205 mL 2.6024 mL 5.2048 mL10 mM 0.2602
3、mL 1.3012 mL 2.6024 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Scopolamine hydrobromide親和的 (nM 級別) 毒蕈堿 (muscarinic) 拮抗劑。Scopolamine 可逆抑制 5-HT3 受體反應,IC50 為 2.09 M。1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEIC50 & Target 5-HT3 Receptor mAChR2.09 M (IC50)體外研究 Application
4、 of Scopolamine to oocytes expressing 5-HT3 receptors does not elicit a response when appliedalone, but causes a concentration-dependent inhibition of the response during a co-application of 2 M 5-HT.The pIC50 value for Scopolamine is 5.680.05 (IC50=2.09 M, n=6) with a Hill Slope of 1.06 0.05. Thisg
5、ave a Kb of 3.23 M. The same concentration-dependent effect is also seen when Scopolamine is appliedduring the 5-HT application. To further test for a competitive binding at the 5-HT3 receptor, the competition ofunlabelled Scopolamine is measured with 3Hgranisetron, an established high-affinity comp
6、etitive antagonistat these receptors. Scopolamine displays concentration-dependent competition with 0.6 nM 3Hgranisetron(Kd), yielding an average pKi of 5.170.24 (Ki=6.76 M, n=3) 1.體內(nèi)研究 In the histopathology study, there is no significant change in the histology of the brain. However, it isobserved
7、that there is a reduction in density of cells in the hippocampus of the control mice pretreated withScopolamine who received only distilled water 2. Scopolamine administration alone significantly increasesthe activity of Acetylcholinesterase enzyme (AchE) (7.980.065; P1-42) (P 3.PROTOCOLKinase Assay
8、 1 Saturation binding (8 point) curves are measured by incubating either crude extracts of HEK 293 cells stablyexpressing 5-HT3 receptors, or Guinea pig membrane preparations, in 0.5 mL incubations containing 10 mMHEPES buffer (pH 7.4) and 0.1-1 nM 3Hgranisetron or 1-10 nM 3HN-methylScopolamine. Com
9、petitionbinding (10 point) is determined by incubating the same receptors preparations in 0.5 mL HEPES buffercontaining either 0.6 nM 3Hgranisetron or 0.6 nM 3HN-methylScopolamine, and differing concentrations ofcompeting ligands. Non-specific binding is determined with 1 mM quipazine or 10 M Scopol
10、aminerespectively. Incubations are terminated by filtration onto Whatman GF/B filters wetted with HEPESbuffer+0.3% polyethyleneimine, followed by two rapid washes with ice-cold HEPES buffer. Proteinconcentration is calculated using a Lowry protein assay with bovine serum albumin standards. Radioacti
11、vityis measured using a Tri-Carb 2100 TR scintillation counter 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 2Administration 23 The mice are weighed, labeled and grouped into seven groups of 5 animals each after which all animals arepre-
12、injected intraperitoneally with 3 mg/kg Scopolamine. Groups 1-3 are administered 0.2 mL equivalentdoses of 4 mg/kg, 6 mg/kg and 8 mg/kg of the extract of Morinda lucida while groups 4-6 are given samedoses of Peltophorum pterocarpum extract and group 7 is given 0.2 mL of distilled water (negative co
13、ntrol)for 3 consecutive days.Rats 3Healthy male Wistar rats (12 months old) weighing 180200 g are used in this study. Rats are divided intofive groups (n=6/group); Group I-normal control, Group II-disease control (Scopolamine hydrobromide 3mg/kg, i.p.), Group III-Scopolamine+Quercetin (25 mg/kg, p.o
14、.), Group IV-standard treatment(Scopolamine+Donepezil hydrochloride 3 mg/kg, p.o.), and Group V-Scopolamine+Quercetin (25 mg/kg,p.o.)+Donepezil (3 mg/kg, p.o.). Group III, IV, and V rats are dosed every 24 h interval with respective drugs2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEfor 14 consec
15、utive days. The acquisition trail for Morris water maze, elevated plus maze, and passiveavoidance paradigm is carried out on the 14th day, and Scopolamine (3 mg/kg, i.p.) is administered on the14th day after the acquisition trail to all groups except normal control group, which provoke the cognitive
16、impairment in rats. Retention of memory is tested on the 15th day, and on the same day, rats are sacrificedand brain tissues are isolated to estimate acetylcholinesterase enzyme (AchE) and brain oxidative stressmarkers such as lipid peroxidase (LPO), glutathione (GSH) (reduced). ELISA kit is used to
17、 estimate amyloid (A1-42) level. The hippocampus of rat brains is dissected out and studied for histopathologicalchanges.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Lochner M, et al. The muscarinic antagonists Scopolamine and atropine a
18、re competitive antagonists at 5-HT3 receptors.Neuropharmacology. 2016 Sep;108:220-8.2. O ET, et al. COGNITIVE-ENHANCING PROPERTIES OF MORINDA LUCIDA (RUBIACEAE) AND PELTOPHORUM PTEROCARPUM(FABACEAE) IN SCOPOLAMINE-INDUCED AMNESIC MICE. Afr J Tradit Complement Altern Med. 2017 Mar 1;14(3):136-141.3. Pattanashetti LA, et al. Evaluation of neuroprotective effect of Quercetin with Donepezil in Scop
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 微電網(wǎng)發(fā)電機組與儲能系統(tǒng)的多目標優(yōu)化設計考核試卷
- 投標文件編制中的成本控制要點考核試卷
- 廢料處理技術創(chuàng)新與應用考核試卷
- 農(nóng)村土地租賃合同中的租賃物保險制度解析考核試卷
- 2025年中國PP聚丙烯塑料漆數(shù)據(jù)監(jiān)測報告
- 2025年中國PB地板采暖管數(shù)據(jù)監(jiān)測報告
- 2025年中國COD消解加熱器數(shù)據(jù)監(jiān)測研究報告
- 2025年中國3-辛酮數(shù)據(jù)監(jiān)測報告
- 高支模板工程培訓
- 2025至2030年中國食堂自動售飯結算系統(tǒng)市場分析及競爭策略研究報告
- NIH-FDA-IND-IDE-II期III期臨床試驗方案模板
- 2025春季學期國開電大??啤缎姓M織學》一平臺在線形考(形考任務1至5)試題及答案
- 腫瘤患者全程健康管理
- T-CNAS 18-2020 成人住院患者跌倒風險評估及預防
- 腹股溝疝嵌頓病人的護理
- 《特種設備重大隱患判定標準(陜西?。方庾x與培訓
- 《收益法在無形資產(chǎn)價值評估中的應用案例分析:以M生物公司為例》8900字(論文)
- 重慶市森林資源二類調查操作細則2012年
- IEC31010-2019風險管理 風險評估技術(雷澤佳譯-2024)
- 新生兒黃疸的護理常規(guī)
- ISOIEC38507-2022信息技術-IT治理-組織使用人工智能的治理影響(中文版-雷澤佳譯2024)
評論
0/150
提交評論